Market LIVE
Published markets; coverage varies by country
Product profile · United States

REVUFORJ

 ·  Patent Litigation & Settlement History ↓

IngredientREVUMENIB CITRATE
Application typeNDA
Application218944
Product001
Dosage formTABLET
RouteORAL
StrengthEQ 25MG BASE
Approval date2024-11-15
Marketing statusPrescription
Status event—
ApplicantSYNDAX
Product source

Current GenericRadar decision

Year2037
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2037-06-08
Patent anchor2037-06-08
Exclusivity anchor2029-11-15
Protection date—
First Final ANDA—
Status event—

QUALIFYING_ANCHOR_WITH_LATER_RIGHTS; REVUFORJ: KMT2A ODE combination excludes current NPM1 indication; NPM1 ODE end TBD, no approval-plus-seven-year inference.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
106833022037-06-08DS/DP ————
———
114795572037-06-08DP/U U-4327———
———
114795572037-06-08DP/U U-4045———
———
125645902042-12-18DP/U U-4327———
———
125645902042-12-18DP/U U-4045———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE—2029-11-15YY——Source
ODE-502—2031-11-15————Source
ODE-504—2031-11-15————Source
ODE-505—2031-11-15————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.